Lactobacillus paracasei (K71 / LP33) for Eczema
Verdict: Disputed
Across 5 PubMed studies, the evidence for Lactobacillus paracasei (K71 / LP33) in Eczema grades Tier D — counter-evidence. High-quality studies disagree — the evidence is genuinely mixed.
D 🔴 D Counter-Evidence Disputed
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.40
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Disputed
Confidence
60%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.395
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 0 positive)，下層 RCT 不能推翻
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Single-Strain Probiotic Lactobacilli for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis
Finding: L. paracasei subgroup showed NON-significant SCORAD reduction (MD -7.39; 95% CI -19.08 to 4.29; p=0.21); overall single-strain pooled MD -4.50 (95% CI -7.50 to -1.49; p=0.003) but driven by L. fermentum.
View on PubMed Efficacy of probiotics in pediatric atopic dermatitis: A systematic review and meta-analysis
Finding: Probiotics overall reduced SCORAD (MD -4.24; 95% CI -7.78 to -0.71; p=0.002); single-strain effective (MD -3.85, p=0.04), multi-strain non-significant (p=0.2); did not isolate L. paracasei specifically.
View on PubMed A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated Lactobacillus paracasei Supplement in Infants with Atopic Dermatitis Receiving Topical Corti…
Finding: SCORAD decreased significantly over time in both arms (p<0.001) with NO between-group difference; no corticosteroid-sparing effect for L. paracasei vs placebo.
View on PubMed Children with atopic dermatitis show clinical improvement after Lactobacillus exposure (Wang IJ, Taiwan)
Finding: LP, LF, and LP+LF groups all showed significantly lower SCORAD than placebo (p<0.001) in children aged 1-18; benefit persisted at 4-month follow-up.
View on PubMed Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema
Finding: No significant difference between L. paracasei and placebo arms after 12-week treatment (p=0.7); all groups improved but no probiotic-specific benefit.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L5a NIH Office of Dietary Supplements
Cautious
A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
Conditional recommendations are made against early food introduction, human milk consumption, and probiotic or vitamin D supplementation for AD prevention. source↗